RS
Raghul Senthilnathan
Also known as: Raghul S
Cogniverse Limited, Medilink East Midlands, University College London, Vellore Institute of Technology University
Research areas: Biochemistry, Genetics and Molecular Biology · Cancer Research · MicroRNA in disease regulation · Head and Neck Cancer Studies · Cancer-related molecular mechanisms research
Employment
-
Cogniverse Limited Founder & CEO2023 - Present
Education
-
University College London Biotech and Pharmaceutical management2022 - 2023
-
Vellore Institute of Technology University Biotechnology2018 - 2022
Projects & Funding
Projects & funding information is unavailable.
Publications (10)
- Exploring resilience and innovation in law SMEs: Navigating global disruptions in the era of AI and digital transformation Save
- Bio-inspired nanoparticles mediated from plant extract biomolecules and their therapeutic application in cardiovascular diseases: A review Save
- An update on CRISPR-Cas12 as a versatile tool in genome editing Save
- A Clinical Investigation on the Theragnostic Effect of MicroRNA Biomarkers for Survival Outcome in Cervical Cancer: A PRISMA-P Compliant Protocol for Systematic Review and Comprehensive Meta-Analysis Save
- Conceptual and Statistical Interpretation of a Systematic Review and Meta-Analysis on Patient Adherence to Lung-RADS–Recommended Screening Intervals in the United States Save
- Conceptual interpretation and clinical applicability of a systematic review and meta-analysis about prognostic value of apolipoproteins in COVID-19 patients Save
- Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol Save
- Clinical comments on “Mental disorder prevalence among populations impacted by coronavirus pandemics: A multilevel meta-analytic study of COVID-19, MERS & SARS” Save
- A Clinical Update on the Prognostic Effect of microRNA Biomarkers for Survival Outcome in Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis Save
- Clinical comments on prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma (OSCC). Save